Cantor Fitzgerald Has Lowered Expectations for AbbVie (NYSE:ABBV) Stock Price

AbbVie (NYSE:ABBV) had its price target decreased by Cantor Fitzgerald from $250.00 to $240.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Cantor Fitzgerald’s target price suggests a potential upside of 12.92% from the company’s current price.

A number of other equities research analysts have also recently issued reports on the company. HSBC upgraded AbbVie from a “hold” rating to a “buy” rating and boosted their price objective for the company from $225.00 to $265.00 in a research note on Wednesday, December 10th. Berenberg Bank set a $275.00 price objective on AbbVie in a research note on Tuesday, January 20th. Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a research note on Thursday, February 5th. Morgan Stanley boosted their price objective on AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and an average price target of $252.65.

AbbVie Stock Performance

Shares of AbbVie stock opened at $212.54 on Wednesday. AbbVie has a 52-week low of $164.96 and a 52-week high of $244.81. The stock’s 50-day simple moving average is $220.65 and its 200 day simple moving average is $224.11. The stock has a market capitalization of $375.81 billion, a P/E ratio of 90.06, a P/E/G ratio of 0.76 and a beta of 0.38.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The business had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. During the same period in the previous year, the business posted $2.16 EPS. The firm’s quarterly revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities research analysts forecast that AbbVie will post 12.31 EPS for the current fiscal year.

Insider Transactions at AbbVie

In other news, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares in the company, valued at approximately $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 0.06% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of AbbVie by 1.7% in the fourth quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company’s stock worth $41,306,353,000 after purchasing an additional 3,032,438 shares during the last quarter. State Street Corp increased its position in shares of AbbVie by 1.4% in the fourth quarter. State Street Corp now owns 80,940,931 shares of the company’s stock worth $18,494,193,000 after purchasing an additional 1,119,274 shares during the last quarter. Geode Capital Management LLC increased its position in shares of AbbVie by 10.4% in the fourth quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock worth $10,179,099,000 after purchasing an additional 4,190,487 shares during the last quarter. Bank of America Corp DE increased its position in shares of AbbVie by 1.4% in the fourth quarter. Bank of America Corp DE now owns 25,824,399 shares of the company’s stock worth $5,900,617,000 after purchasing an additional 356,394 shares during the last quarter. Finally, Norges Bank bought a new position in shares of AbbVie in the fourth quarter worth approximately $5,865,055,000. 70.23% of the stock is currently owned by institutional investors.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Seeking Alpha published an upgrade framing AbbVie as a “buy, but with caveats” ahead of Q1 results — the piece highlights upside potential from the immunology franchise and portfolio renewal, which can support investor confidence. AbbVie: Buy Or Sell Ahead Of Q1 Earnings? It’s A Buy, But With Caveats (Upgrade)
• Positive Sentiment: Cantor Fitzgerald kept an overweight rating while trimming its price target to $240 — still signaling meaningful upside from current levels and providing support for the stock. Cantor Fitzgerald price target note
• Positive Sentiment: New dermatology data presented at the AAD meeting (Skyrizi and Rinvoq) reinforce AbbVie’s growth story in immunology/dermatology, supporting medium‑term revenue and dividend reliability. Can AbbVie’s (ABBV) New Dermatology Data Quietly Reshape Its Immunology-Heavy Investment Story?
• Neutral Sentiment: AbbVie appears in several dividend and income investor roundups as a Dividend Aristocrat with a ~3.3% yield and a long streak of dividend growth — this underpins the stock’s defensive appeal but is not an immediate catalyst. 3 Dividend Aristocrats Whose Yields Can Help Combat Inflation
• Neutral Sentiment: AbbVie filed suit seeking clarification of eligibility rules in a U.S. drug discount program — if successful this could protect pricing and margins, but it also introduces litigation risk and timing uncertainty. AbbVie files lawsuit to address ‘outdated’ drug discount eligibility program
• Neutral Sentiment: Corporate/PR items (BOTOX® Cosmetic entrepreneurship program) and “trending stock” writeups (Zacks/Yahoo) keep ABBV in investor headlines but are unlikely to move the stock materially by themselves. BOTOX® Cosmetic empowers women entrepreneurs
• Negative Sentiment: AbbVie reduced guidance: Q1 2026 EPS was updated to a range of 2.560–2.600 (consensus ~3.010) and FY 2026 EPS to 13.960–14.160 (consensus ~14.560). The downward revisions are the principal near‑term negative catalyst, increasing downside risk to near‑term estimates and valuation multiples.
• Negative Sentiment: Competitive/marketing signals: J&J’s Tremfya reclaimed the top spot in TV drug ad spending from AbbVie — a small but tangible sign of competitive pressure in immunology promotion and share battles. J&J’s Tremfya retakes TV drug ad spending crown from AbbVie

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.